Heat Biologics, Inc. HTBX
Day range unavailable
52-week range unavailable
Discussion (514)
Sign in to join the discussion
UP UP Up
NASDAQ: HTBX is set for a 7% increase on Thursday, following Wednesday's leap of the same scale.
Speculation that Heat Biologics may receive a government grant may continue fueling the rally.
Promising pre-clinical data in its coronavirus-vaccine candidate is keeping the stock bid.
The race to develop immunization for coronavirus vaccine is warming up – with Heat Biologics (NASDAQ: HTBX) gaining speed. The Morrisville, North Carolina based firm has yet to generate revenue – but it may receive support from Uncle Sam. The US government has been generously awarding funds to firms working on immunization to COVID-19 – including Kodak, a company that filed for Chapter 11.
Funding is coming, The race to develop immunization for coronavirus vaccine is warming up – with Heat Biologics (NASDAQ: HTBX) gaining speed. The Morrisville, North Carolina based firm has yet to generate revenue – but it may receive support from Uncle Sam. The US government has been generously awarding funds to firms working on immunization to COVID-19 – including Kodak,
Shorts are gone, and tomorrow they will have to buy at a much bigger price
Heat Biologics COVID-19 Vaccine Demonstrates Immunogenicity Proof-of-Concept in Pre-Clinical Studies
ACCESSWIREJuly 29, 2020, 1:30 PM
Confirms stimulation of human-HLA-restricted transgenic mouse T-cells against immunodominant epitopes of SARS-CoV-2 Spike protein
DURHAM, NC / ACCESSWIRE / July 29, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced successful pre-clinical testing of the Company's COVID-19 vaccine
While Heat is well behind the leaders in the race to develop a COVID-19 vaccine, these positive preclinical data could open the door for a lucrative collaboration with a big-name pharma or perhaps a sizable government grant. The U.S. federal government has been extremely generous in terms of funding when it comes to developmental-stage coronavirus vaccines in general.